Abstract. Laryngeal squamous cell carcinoma (LSCC) is one of the most prevalent types of head and neck malignancies. Advanced LSCC has failed to demonstrate a satisfactory prognosis, despite the progresses in the diagnosis and treatment, and the optimal treatment modality continues to be debated. To evaluate the clinical utility and survival outcomes of adjuvant chemoradiotherapy (CRT) for patients with resected advanced LSCC, a retrospective analysis of 232 patients with LSCC who had undergone total laryngectomy and neck dissection between 2005 and 2010 was conducted. Of the 232 eligible patients, 167 patients (72%) received surgery alone, whereas 65 patients (28%) received surgery + adjuvant CRT. In the overall cohort, the 5-and 10-year overall survival (OS) rates were 55.2 and 48.3%, respectively. Multivariate analysis revealed that the clinical stage was significantly associated with OS. However, the N classification was an independent indicator in disease-free survival and laryngeal cancer-specific survival. In those patients with stage IV disease, patients receiving adjuvant CRT exhibited a markedly improved survival benefit compared with patients receiving surgical treatment only, following propensity score matching of the data (P<0.05). The application of adjuvant CRT confers additional survival benefits in comparison with surgery-only treatment regimens for advanced LSCC. However, additional prospective studies are required.
Introduction
Laryngeal squamous cell carcinoma (LSCC) is one of the most prevalent types of head and neck malignancies, and it has an estimated incidence of 5.1-10 cases per 100,000 worldwide (1) . The majority of patients (~60%) present with stage III or stage IV disease at diagnosis (2) . LSCC has been one of the few cancer types with a decreased survival outcome over the past 40 years in the United States of America (2, 3) . Due to the large population, China has reported ~13.0% of laryngeal cancer (LC) cases and 14.7% of LC-specific mortalities within the global LC population (4) .
The treatment modalities for LSCC include surgery, chemotherapy, radiotherapy or the combination of these therapies (1, 5) . Adjuvant chemoradiotherapy (CRT) is recommended for resected locally advanced head and neck cancer with positive surgical margins or extracapsular extension, according to 2 randomized clinical trials: The Intergroup Radiation Therapy Oncology Group (RTOG) 95-01 and European Organization for Research and Treatment of Cancer 22931 (6) (7) (8) . Advanced LSCC has failed to demonstrate a satisfactory prognosis despite the progress in the diagnosis and treatment of LSCC, and the optimal treatment modality continues to be debated (9) (10) (11) .
Previous study on the treatment of LSCC has focused on the comparison between primary radiotherapy and CRT (12) , and there have been few studies performed to compare surgery and surgery + adjuvant CRT for patients with advanced LSCC. The aim of the present study was to determine the clinical effect of adjuvant CRT for patients with advanced LSCC who underwent initial surgeries in a single institution over a 10-year post-treatment follow-up.
Materials and methods
Patient selection. The medical records of patients with previously untreated LSCC were retrospectively reviewed. Treatment and follow-up. All the patients were initially treated with total laryngectomy and neck dissection. The type of neck dissection depended on the particular clinical situation. Adjuvant CRT was primarily performed in cases of pN2+ stage disease (according to the AJCC TNM staging system, 7th edition) or in cases of positive surgical margins and/or extracapsular spread in the pathological examination (13) . Physical examination and computerized tomography were performed for regular follow-up if required. For the first 2 years, follow-up was performed every 1-3 months. Subsequently, it was performed every 4-6 months for the third year. Following that, the follow-ups continued annually until the end of the study period. No patients were lost to follow-up.
Statistical analysis. Descriptive statistics were compiled to characterize the patients receiving surgery vs. surgery + adjuvant CRT. The differences between these two groups were evaluated using a χ 2 test or Fisher's exact test for categorical variables. Time-to-event was measured from the date of initial surgical resection. Outcome measures were laryngeal cancer-specific survival (CSS), overall survival (OS) and disease-free survival (DFS). Patients were censored at the time of their last follow-up. Survival times were calculated from the day of surgery to the date of occurrence of an event or from the date of the last follow-up. Survival outcomes were calculated using the Kaplan-Meier method. The differences between survival curves were analyzed using a log-rank test. Univariate and multivariate analyses of survival outcomes were accomplished using Cox proportional hazards modeling. Variables with P<0.05 in the univariate analysis were entered into the multivariate analysis to determine independent indicators of treatment outcome. Propensity-score matching (PSM) was then performed to decrease the effects of potential confounding factors: One-to-one propensity matching without replacement was completed using the nearest-neighbor matching algorithm (14, 15) . Analyses were performed using the SPSS v24.0 statistical software package (IBM Corporation, Armonk, NY, USA) and Stata 14.0 (StataCorp LP, College Station, TX, USA). All statistics were double-sided, and P<0.05 was considered to indicate a statistically significant difference.
Results

Patient characteristics.
A total of 232 patients with LSCC [230 males (99.2%) and 2 females (0.8%)] were included in the present study (Table I ). The median age was 61.0 years (range, 36-82 years) and 59.1% (137 patients) were ≥60 years of age. At diagnosis, 83 patients (35.8%) were diagnosed with stage III disease, while 149 patients (64.2%) were diagnosed with stage IV disease. N classification included N0 (n=45; 19.4%), N1 (n=61; 26.3%), N2 (n=108; 46.6%) and N3 (n=18; 7.8%). In total, 167 patients received surgery, and 65 patients received surgery + adjuvant CRT. An increased number of patients with N+ disease received adjuvant CRT compared with those patients with N0 disease (31.0 vs. 18.4%). Of all the 232 patients, 25 patients exhibited positive surgical margins and/or extracapsular spread, and they were all in the surgical + adjuvant CRT group.
Survival analysis. The median follow-up for all patients was 46.8 months (range, 4.9-140.8 months). Of the 232 patients, 114 patients (49.1%) succumbed to LSCC and 6 patients (2.6%) succumbed as a result of other causes. Cumulatively, the 3/5-year OS, DFS and CSS rates were 69.4/55.2, 58.6/47.4 and 69.4/56.5%, respectively. Prognostic factors for a poorer OS identified in the univariate analysis were age (<60 vs. ≥60 years; P= 0.045), N classification (N0 vs. N+; P= 0.006) and clinical stage (III vs. IV; P= 0.004). N classification and stage were also statistically significant factors in DFS and CSS according to univariate analysis (P<0.05; Table II) . No differences regarding primary tumor localization, T classification, smoking and alcohol consumption history were demonstrated for these 3 endpoints. Multivariate analysis revealed that age (<60 vs. ≥60 years; P= 0.035) and stage (III vs. IV; P= 0.022) were statistically significant factors in OS, whereas N classification (N0 vs. N+) was the independent factor in DFS (P=0.015) and CSS (P=0.043) ( Table III) .
Comparison of treatment modalities prior to and following PSM. As the N classification and clinical stage were the significant indicators from the survival analysis and they were not well balanced for the surgery and surgery + CRT groups, PSM was additionally performed to obtain a matched cohort and to investigate if there were any survival differences between the two groups (16) (17) (18) . The patient characteristics following matching with well-balanced N classification and stage are summarized in Table IV . Prior to PSM, there was no statistical significance between the two treatment groups by log-rank tests, but it appeared that the surgery-only group may have exhibited improved survival outcomes compared with the surgery + CRT group in OS and CSS (Fig. 1) . Following PSM, it was revealed that patients who underwent surgery + CRT exhibited an improved survival outcome compared with patients who only underwent surgery (Fig. 2) . Following stratification by stage, patients at stage IV continued to exhibit an improved survival benefit in the surgery + CRT group compared with the surgery-only group for all 3 endpoints. No significant difference in OS or CSS was observed in patients with stage III disease (Fig. 3 ). For patients with pN2 disease, no statistical significance was observed between the two groups. Following matching the T stage, patients with pN2 stage LC exhibited an improved survival benefit in the surgery + CRT group compared with the surgery-only group (Fig. 4) .
Discussion
Previously, the primary approach to therapy for advanced LSCC was surgical treatment (19, 20) . At present, multiple treatment modalities, including radiotherapy and chemoradiotherapy, have been introduced to treat advanced LSCC.
These were based on published clinical trials that revealed that increased rates of larynx preservation may be obtained Table I . Baseline patient characteristics in the 232 unmatched patients with resected laryngeal cancer who had undergone surgery alone or surgery with adjuvant CRT.
Treatment groups, no. of patients (%) Overall survival Disease-free survival Cancer-specific survival with chemoradiotherapy for advanced LC (21, 22) . However, different treatment modalities or combinations have varied in different developing and developed countries (23) . Several clinical trials have been conducted to investigate the optimal treatment for LC (21, 24, 25) . The Veterans Administration randomized clinical trial (RCT) comprising two treatment arms revealed that the usage of primary CRT offered patients who underwent surgery an equal survival chance (17) . Concomitantly, the CRT group had a two-thirds likelihood of preservation of the larynx for stage III/IV laryngeal cancer (21) . An additional RCT, the RTOG 91-11 trial, comprising three treatment arms (induction chemotherapy + radiation (RT) vs. concurrent CRT vs. RT) indicated superior locoregional control and larynx preservation rate in the concurrent CRT treatment arm; however, no difference was observed in OS (22) . The updated 10-year follow-up for the RTOG 91-11 study revealed that there was a trend toward a poorer survival in the concurrent CRT treatment arm, which may be attributed to the increased incidence of toxicity (24). Table IV . Baseline patient characteristics in the 130 propensity score-matched patients with resected laryngeal cancer who had undergone surgery alone or surgery with adjuvant CRT. There has been a decreased survival rate in laryngeal cancer in previous decades with the increased application of different treatment approaches (26) . Hoffman et al (26) suggested that RT alone or CRT was correlated with an increased mortality rate compared with surgery in T3 glottic cancer. An RCT conducted in France including patients with T3 primary laryngeal tumors demonstrated significantly improved survival in the group undergoing immediate surgery compared with patients receiving induction chemotherapy followed by RT (25). Previous studies revealed that the 5-year OS and DFS rates in patients with advanced LC were 60.8-71.6 and 41.0-57.8%, respectively, with regard to different treatment regimens (23, 27) . The present study demonstrated that the 5-year OS and DFS rates were 55.2 and 47.4%, respectively, which supported previously published data.
Overall survival Disease-free survival Cancer-specific survival ------------------------------------------------------------------------------------------------------------------------------------------------------------------
Treatment groups, no. of patients (%) -----------------------------------------------------------------------------------------------
Studies have indicated that the lymph node status is one of the most significant prognostic factors in patients with LC (28, 29) . Smoking and being of an elderly age are also risks factors in patients with LC, but the effects of age in the prognosis of LC remain controversial (30) (31) (32) . The multivariate analysis in the present study demonstrated that the patients' clinical stage and nodal status were independent indicators in survival outcome. Age was statistically significant in univariate analysis, but it was not an independent factor. Smoking was not a risk factor in the present study and requires verification with an increased number of study participants. Furthermore, there is a concern for the long-term toxicity and for the methods of selecting patients utilizing surgical or non-surgical treatments as the primary treatment strategies (24, 33) . Treatment varies in different geographical locations as there is currently no optimal treatment in clinical practice (34) . Certain studies have supported the hypothesis that postoperative RT does not provide additional survival effects in patients with LC, while other studies have suggested that patients receiving surgery with postoperative RT have improved survival (32, 35, 36) . Chen and Halpern (37) demonstrated almost equivalent efficacy for CRT and total laryngectomy for stage III disease, but significant differences in survival for all patients with advanced LC in a hospital-based study. Analysis of the National Cancer Data Base revealed that patients with stage III and IV disease treated with surgery as the primary treatment strategy had improved 5-year relative survival compared with those treated with irradiation (with or without chemotherapy) among 158,426 LC cases (26) . A cross-section study using Surveillance, Epidemiology and End Results-Medicare data demonstrated that an improved survival benefit was observed following surgery with adjuvant RT of the whole LC cohort (36) . However, there remains a paucity in the current literature of data to provide detailed descriptions of the comparison of the treatment modalities for advanced LSCC. In the present study, 232 patients with advanced LSCC were compared with 2 treatment modalities: Surgery vs. surgery + CRT. The results revealed that patients who underwent surgery + adjuvant CRT had improved survival outcomes compared with patients who were treated with surgery alone in the overall cohort. Subsequent stratification demonstrated that the clinical effect was limited in patients with pN2 disease and patients with stage IV disease. The inadequate patient number meant that whether patients with stage III LC would receive a survival benefit with adjuvant CRT could not be discerned. Additional studies will be required in the coming years to elucidate the causes of this apparent decrease in larynx cancer survival, and/or improve the selection of patients for surgical and non-surgical treatments.
Several limitations of the present study should be noted: In the subgroup analysis, with regard to the potential benefit from the adjuvant CRT in patients with or without positive surgical margins, the benefit of adjuvant CRT in the subgroup of patients with positive surgical margins was not determined, as all the patients with positive surgical margins were in the surgical + adjuvant CRT group. For the patients with pN2+ disease, no statistical significance was observed among the unmatched 232 patients. Following matching, an additional survival benefit was observed in the patients with LC receiving adjuvant CRT. In addition, as LSCC is a predominantly male disease, and because there were a limited number of females in the present study due to the relatively small sample size, the potential effects of sex were not assessed.
In conclusion, patients with stage IV LSCC may benefit from adjuvant CRT following initial total laryngectomy. It is worth noting that a significant limitation of the present study was its retrospective design. As it includes the data from only 1 institution, the results require validation by a prospective multicenter study.
